Obesity Rates Surge Across America: The Impact of Ozempic and State Perspectives

Obesity Rates Surge Across America: The Impact of Ozempic and State Perspectives

Recent agreements set forth by President Donald Trump aim to lower prices on widely-used weight-loss drugs. As a result, the adoption of GLP-1 medications like Ozempic and Mounjaro is expected to rise significantly, but this trend is unevenly distributed across the United States. Certain states are witnessing a much greater increase in usage than others.

A comprehensive report by Purple Lab, a health analytics firm from Pennsylvania, utilized insurance claims data to assess prescription trends for weight-loss and diabetes medications. This 2024 study, released by GLP-1 Newsroom, details the estimated volume of GLP-1 prescriptions on a state-by-state basis.

It is crucial to note that the prescription records exclusively reflect data from commercial and government insurers. Consequently, they do not account for individuals who paid cash, sought treatment through telehealth providers, utilized compounded versions of the drugs, or remained uninsured. Thus, the actual figures likely exceed those reported.

States Leading in GLP-1 Prescriptions

The report highlighted states where more than 15% of the population received GLP-1 prescriptions for either weight loss or diabetes management. The highest rates of usage were observed primarily in the South, Midwest, and Appalachia, regions that generally struggle with elevated obesity and diabetes prevalence.

Identifying the Lowest Usage States

Conversely, states with the lowest GLP-1 prescription rates tend to be located along the coasts and in the western part of the country. Notably, Hawaii recorded the least amount of prescriptions overall.

Expert Insights on GLP-1 Medications

Dr. Brett Osborn, a neurologist and longevity specialist based in Florida, frequently prescribes GLP-1 medications to his patients. He personally takes a daily microdose to enhance heart health.

Dr. Osborn elaborated on the primary usage of these medications, stating, “These agents are primarily prescribed for type 2 diabetes, but the tides are turning. In my humble opinion, they will be utilized more for obesity treatment in people who do not have diabetes, although there is often significant overlap between these conditions.”

Looking ahead, Dr. Osborn predicts that GLP-1 medications may find applications in treating or preventing vascular disease, reducing alcohol consumption, addressing gambling addiction, decelerating cognitive decline, and potentially serving as adjuncts to chemotherapy for cancer treatment.

He cautioned, “Prescribing practices and indications are evolving rapidly, and we must tread carefully with our conclusions. Nevertheless, I suspect these medications are being prescribed more in states like Kentucky and West Virginia, where obesity and diabetes rates are high.”

Insights from Trust for America’s Health

The Trust for America’s Health recently published its State of Obesity report, utilizing 2024 data derived from the CDC’s Behavioral Risk Factor Surveillance System. The report identified ten U.S. states with the highest adult obesity rates, all of which are situated in either the South or Midwest.

Remarkably, in nine of these ten states, at least 15% of the population holds GLP-1 prescriptions based on the insurance claims data examined.

Shifts in National Obesity Rates

Overall, the data indicated that 19 states reported adult obesity rates reaching or exceeding 35%, a decrease from 23 states in the previous year. Additionally, this marks the first instance where no state registered an adult obesity rate below 25%, illustrating a troubling national trend.

States Boasting the Lowest Obesity Rates

The report further details states with the lowest obesity rates, drawing attention to structural barriers limiting access to healthy eating and physical activity. J. Nadine Gracia, M.D., president and CEO of Trust for America’s Health, commented on the pressing need for continued policy attention and investment to address these challenges.

Dr. Gracia emphasized the importance of governmental and organizational investments in proven programs that promote good nutrition and physical activity, ensuring that these initiatives benefit all communities.

Looking Ahead

The landscape of obesity and weight management in America continues to evolve, shaped by emerging treatments like GLP-1 medications. As states confront various challenges posed by obesity and related health issues, the role of public health initiatives and accessible treatment options remains critical for managing these trends.

Fox News Digital sought comments from manufacturers of GLP-1 medications regarding their insights into the ongoing shifts in obesity management and treatment accessibility across the United States.